Cargando…
Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics
To develop a carrier for use in enzyme prodrug therapy, Horseradish peroxidase (HRP) was immobilized onto mesoporous silica nanoparticles (IBN-4: Institute of Bioengineering and Nanotechnology), where the nanoparticle surfaces were functionalized with 3-aminopropyltrimethoxysilane and further conjug...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304787/ https://www.ncbi.nlm.nih.gov/pubmed/28347114 http://dx.doi.org/10.3390/nano5042169 |
_version_ | 1782506946542174208 |
---|---|
author | Hung, Bau-Yen Kuthati, Yaswanth Kankala, Ranjith Kumar Kankala, Shravankumar Deng, Jin-Pei Liu, Chen-Lun Lee, Chia-Hung |
author_facet | Hung, Bau-Yen Kuthati, Yaswanth Kankala, Ranjith Kumar Kankala, Shravankumar Deng, Jin-Pei Liu, Chen-Lun Lee, Chia-Hung |
author_sort | Hung, Bau-Yen |
collection | PubMed |
description | To develop a carrier for use in enzyme prodrug therapy, Horseradish peroxidase (HRP) was immobilized onto mesoporous silica nanoparticles (IBN-4: Institute of Bioengineering and Nanotechnology), where the nanoparticle surfaces were functionalized with 3-aminopropyltrimethoxysilane and further conjugated with glutaraldehyde. Consequently, the enzymes could be stabilized in nanochannels through the formation of covalent imine bonds. This strategy was used to protect HRP from immune exclusion, degradation and denaturation under biological conditions. Furthermore, immobilization of HRP in the nanochannels of IBN-4 nanomaterials exhibited good functional stability upon repetitive use and long-term storage (60 days) at 4 °C. The generation of functionalized and HRP-immobilized nanomaterials was further verified using various characterization techniques. The possibility of using HRP-encapsulated IBN-4 materials in prodrug cancer therapy was also demonstrated by evaluating their ability to convert a prodrug (indole-3-acetic acid (IAA)) into cytotoxic radicals, which triggered tumor cell apoptosis in human colon carcinoma (HT-29 cell line) cells. A lactate dehydrogenase (LDH) assay revealed that cells could be exposed to the IBN-4 nanocomposites without damaging their membranes, confirming apoptotic cell death. In summary, we demonstrated the potential of utilizing large porous mesoporous silica nanomaterials (IBN-4) as enzyme carriers for prodrug therapy. |
format | Online Article Text |
id | pubmed-5304787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-53047872017-03-21 Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics Hung, Bau-Yen Kuthati, Yaswanth Kankala, Ranjith Kumar Kankala, Shravankumar Deng, Jin-Pei Liu, Chen-Lun Lee, Chia-Hung Nanomaterials (Basel) Article To develop a carrier for use in enzyme prodrug therapy, Horseradish peroxidase (HRP) was immobilized onto mesoporous silica nanoparticles (IBN-4: Institute of Bioengineering and Nanotechnology), where the nanoparticle surfaces were functionalized with 3-aminopropyltrimethoxysilane and further conjugated with glutaraldehyde. Consequently, the enzymes could be stabilized in nanochannels through the formation of covalent imine bonds. This strategy was used to protect HRP from immune exclusion, degradation and denaturation under biological conditions. Furthermore, immobilization of HRP in the nanochannels of IBN-4 nanomaterials exhibited good functional stability upon repetitive use and long-term storage (60 days) at 4 °C. The generation of functionalized and HRP-immobilized nanomaterials was further verified using various characterization techniques. The possibility of using HRP-encapsulated IBN-4 materials in prodrug cancer therapy was also demonstrated by evaluating their ability to convert a prodrug (indole-3-acetic acid (IAA)) into cytotoxic radicals, which triggered tumor cell apoptosis in human colon carcinoma (HT-29 cell line) cells. A lactate dehydrogenase (LDH) assay revealed that cells could be exposed to the IBN-4 nanocomposites without damaging their membranes, confirming apoptotic cell death. In summary, we demonstrated the potential of utilizing large porous mesoporous silica nanomaterials (IBN-4) as enzyme carriers for prodrug therapy. MDPI 2015-12-04 /pmc/articles/PMC5304787/ /pubmed/28347114 http://dx.doi.org/10.3390/nano5042169 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hung, Bau-Yen Kuthati, Yaswanth Kankala, Ranjith Kumar Kankala, Shravankumar Deng, Jin-Pei Liu, Chen-Lun Lee, Chia-Hung Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics |
title | Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics |
title_full | Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics |
title_fullStr | Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics |
title_full_unstemmed | Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics |
title_short | Utilization of Enzyme-Immobilized Mesoporous Silica Nanocontainers (IBN-4) in Prodrug-Activated Cancer Theranostics |
title_sort | utilization of enzyme-immobilized mesoporous silica nanocontainers (ibn-4) in prodrug-activated cancer theranostics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304787/ https://www.ncbi.nlm.nih.gov/pubmed/28347114 http://dx.doi.org/10.3390/nano5042169 |
work_keys_str_mv | AT hungbauyen utilizationofenzymeimmobilizedmesoporoussilicananocontainersibn4inprodrugactivatedcancertheranostics AT kuthatiyaswanth utilizationofenzymeimmobilizedmesoporoussilicananocontainersibn4inprodrugactivatedcancertheranostics AT kankalaranjithkumar utilizationofenzymeimmobilizedmesoporoussilicananocontainersibn4inprodrugactivatedcancertheranostics AT kankalashravankumar utilizationofenzymeimmobilizedmesoporoussilicananocontainersibn4inprodrugactivatedcancertheranostics AT dengjinpei utilizationofenzymeimmobilizedmesoporoussilicananocontainersibn4inprodrugactivatedcancertheranostics AT liuchenlun utilizationofenzymeimmobilizedmesoporoussilicananocontainersibn4inprodrugactivatedcancertheranostics AT leechiahung utilizationofenzymeimmobilizedmesoporoussilicananocontainersibn4inprodrugactivatedcancertheranostics |